Cargando…
Targeting BET bromodomain proteins in solid tumors
There is increasing interest in inhibitors targeting BET (bromodomain and extra-terminal) proteins because of the association between this family of proteins and cancer progression. BET inhibitors were initially shown to have efficacy in hematologic malignancies; however, a number of studies have no...
Autores principales: | Sahai, Vaibhav, Redig, Amanda J., Collier, Katharine A., Eckerdt, Frank D., Munshi, Hidayatullah G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5288238/ https://www.ncbi.nlm.nih.gov/pubmed/27283767 http://dx.doi.org/10.18632/oncotarget.9804 |
Ejemplares similares
-
Bromodomain and Extra-Terminal (BET) Domain Protein Inhibitors for Solid Tumor Cancers
por: Nguyen, Martin V., et al.
Publicado: (2020) -
Selective inhibition of BET bromodomains
por: Filippakopoulos, Panagis, et al.
Publicado: (2010) -
Interactome Rewiring Following Pharmacological Targeting of BET Bromodomains
por: Lambert, Jean-Philippe, et al.
Publicado: (2019) -
GLI2-dependent c-MYC upregulation mediates resistance of pancreatic cancer cells to the BET bromodomain inhibitor JQ1
por: Kumar, Krishan, et al.
Publicado: (2015) -
Therapeutic Targeting of BET Bromodomain Proteins in Castration-Resistant Prostate Cancer
por: Asangani, Irfan A., et al.
Publicado: (2014)